Our Team

Our Team

Our Team

Our Team

Our Team

Brahim Domian, M.D., Ph.D.

Chief Scientific Officer

Brahim Domian, M.D., Ph.D., is Chief Scientific Officer at CiRC Biosciences and a biotechnology leader and physician-scientist in cell and gene therapy. He has advanced programs from discovery through first-in-human trials, leading global teams across translational research, CMC, clinical development, and regulatory affairs.

Most recently, he served as Vice President of Cell Therapy R&D at Novo Nordisk, where he built and led the Platform Technologies organization. He established capabilities in gene editing, hypoimmunity, cryopreservation, and drug product delivery to support multiple clinical-stage and next-generation programs. He played a key role in portfolio strategy and prioritization and supported strategic external partnerships. Previously, Dr. Domian was Vice President at BlueRock Therapeutics, where he led the cardiovascular program and advanced first-in-class cell therapies. Earlier, he was on faculty at Harvard Medical School and an attending cardiologist at Massachusetts General Hospital, where he directed an NIH R01-funded laboratory focused on stem cell and tissue engineering for cardiovascular disease.


Dr. Domian, who earned his M.D. and Ph.D. from Stanford University School of Medicine, is ABIM-certified in cardiovascular disease, and has authored more than 40 peer-reviewed publications. He is an inventor on multiple patents and a frequent invited speaker at international scientific symposia.

Brahim Domian, M.D., Ph.D.

Chief Scientific Officer

Brahim Domian, M.D., Ph.D., is Chief Scientific Officer at CiRC Biosciences and a biotechnology leader and physician-scientist in cell and gene therapy. He has advanced programs from discovery through first-in-human trials, leading global teams across translational research, CMC, clinical development, and regulatory affairs.


Most recently, he served as Vice President of Cell Therapy R&D at Novo Nordisk, where he built and led the Platform Technologies organization. He established capabilities in gene editing, hypoimmunity, cryopreservation, and drug product delivery to support multiple clinical-stage and next-generation programs. He played a key role in portfolio strategy and prioritization and supported strategic external partnerships. Previously, Dr. Domian was Vice President at BlueRock Therapeutics, where he led the cardiovascular program and advanced first-in-class cell therapies. Earlier, he was on faculty at Harvard Medical School and an attending cardiologist at Massachusetts General Hospital, where he directed an NIH R01-funded laboratory focused on stem cell and tissue engineering for cardiovascular disease.

Dr. Domian, who earned his M.D. and Ph.D. from Stanford University School of Medicine, is ABIM-certified in cardiovascular disease, and has authored more than 40 peer-reviewed publications. He is an inventor on multiple patents and a frequent invited speaker at international scientific symposia.

Brahim Domian, M.D., Ph.D.

Chief Scientific Officer

Brahim Domian, M.D., Ph.D., is Chief Scientific Officer at CiRC Biosciences and a biotechnology leader and physician-scientist in cell and gene therapy. He has advanced programs from discovery through first-in-human trials, leading global teams across translational research, CMC, clinical development, and regulatory affairs.

Most recently, he served as Vice President of Cell Therapy R&D at Novo Nordisk, where he built and led the Platform Technologies organization. He established capabilities in gene editing, hypoimmunity, cryopreservation, and drug product delivery to support multiple clinical-stage and next-generation programs. He played a key role in portfolio strategy and prioritization and supported strategic external partnerships. Previously, Dr. Domian was Vice President at BlueRock Therapeutics, where he led the cardiovascular program and advanced first-in-class cell therapies. Earlier, he was on faculty at Harvard Medical School and an attending cardiologist at Massachusetts General Hospital, where he directed an NIH R01-funded laboratory focused on stem cell and tissue engineering for cardiovascular disease.

Dr. Domian, who earned his M.D. and Ph.D. from Stanford University School of Medicine, is ABIM-certified in cardiovascular disease, and has authored more than 40 peer-reviewed publications. He is an inventor on multiple patents and a frequent invited speaker at international scientific symposia.